Keytruda

Keytruda begins pursuit of rivals in small cell lung cancer

Set for competition with Opdivo. Merck &Co. has gained approval for Keytruda for use in third line treatment of small cell lung cancer (SCLC). ... Merck is already exploring Keytruda’s use in combination with chemotherapy in a phase 3 KEYNOTE-604 study.

Merck bulks up in cancer with $2.2bn Peloton buy

It ties in with CEO Ken Frazier’s pledge to make bolt-on acquisitions to bolster Merck’s internal R&D as it starts to look beyond immuno-oncology powerhouse Keytruda ... Keytruda is already making waves in RCC, having been approved for first-line RCC

Keytruda monotherapy fails in triple negative breast cancer

One such study is Keynote-355, which looks at Keytruda combined with chemotherapy (nab-paclitaxel, paclitaxel, gemcitabine, carboplatin) vs. ... Keytruda is far ahead of all its rivals in terms of revenues, and is set to exceed 8bn in global sales this

Research charity LifeArc cashes $1.2bn royalty from Keytruda

Marketed by MSD (Merck &Co in North America), Keytruda (pembrolizumab) is set to reach sales of $8bn this year, and is the leader in the immunotherapy class redefining cancer treatment – and ... CPPIB Credit Europe, a subsidiary of Canada Pension

Iovance up on good ASCO abstract data for cervical cancer therapy

That compares very well with results seen with Merck &Co’s PD-1 inhibitor Keytruda (pembrolizumab) in recurrent cervical cancer, where studies indicated an ORR of around 14%, while for chemotherapy ... That study shows that the TIL can be given after

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]